Skip to main content

Advertisement

Fig. 6 | Molecular Cancer

Fig. 6

From: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Fig. 6

Inhibitory effects of LL28 on the growth of xenograft tumors and spontaneous lung tumorigenesis. a Left. Schematic diagram of the experiment using the tumor xenograft model. Middle. Antitumor effect of LL28 in vivo. Right. Body weight changes in vehicle- or LL28-treated mice. b The expression of the total and phosphorylated forms of IGF1R and Src was determined by Western blot analysis. Left. Representative results of the total and phosphorylated forms of IGF1R and Src. Actin blots serve as a loading control. Right. Densitometric analysis of the phosphorylated form of IGF1R or Src by comparison with the total expression of the corresponding protein was performed using ImageJ software. c Left. Schematic diagram of the experiment using the KrasG12D/+-driven spontaneous lung tumorigenesis model. Right. Representative images of the lungs (left) and H&E-stained section of the lungs (right) from vehicle or LL28-treated mice. d Microscopic analysis of H&E-stained lung tissues from vehicle- or LL28-treated KrasG12D/+ transgenic mice for lung tumor multiplicity and tumor volume. e Body weight changes in vehicle- or LL28-treated mice. f IHC analyses for evaluating the expression of phosphorylated forms of IGF1R and Src and cleaved caspase 3 (Cl-Cas 3) in the tumors of the lungs from vehicle- or LL28-treated mice. Scale bar: 20 μm. The bars represent the means ± SD; *P < 0.05 and **P < 0.01, as determined by a two-sided Student’s t-test. Con: control

Back to article page